

Article

Design of Olmesartan Medoxomil-loaded Nanosponges for Hypertension and Lung Cancer Treatments

Bjad K. Almutairy ¹, Abdullah Alshetaili ¹, Amer S. Alali ¹, Mohammed Muqtader Ahmed ¹, Md. Khalid Anwer ^{1,*} and M. Ali Aboudzadeh ^{2,*}

¹ Department of Pharmaceutics, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Alkharij 11942, Saudi Arabia; b.almutairy@psau.edu.sa (B.K.A.); a.alshetaili@psau.edu.sa (A.A.); a.alali@psau.edu.sa (A.A.); mo.ahmed@psau.edu.sa (M.M.A.)

² CNRS, University Pau & Pays Adour, E2S UPPA, Institut des Sciences Analytiques et de Physico-Chimie pour l'Environnement et les Matériaux, 64000 Pau, France

* Correspondence: mkanwer2002@yahoo.co.in (M.K.A.); m.aboudzadeh-barihi@univ-pau.fr (M.A.A.)




Figure S1. FTIR spectrum of the pure OLM and OLM-loaded nanosponge carriers. The main characteristic peaks of the pure OLM are shown with dotted vertical lines. These peaks are present, weakened or shifted in OLM-loaded nanosponges (ONS1-ONS4).




Figure S2. Comparative XRD diffractograms of the pure OLM and OLM-loaded nanosponge.




Figure S3. Profiles of different kinetic models for release mechanism of OLM from OLM-loaded nanosponges.